TMA Myositis Research Insights Featuring Kanneboyina Nagaraju, DVM, PhD

Do you use prednisone? You won’t want to miss this webinar!
TMA’s Myositis Research Insights webinar series features a distinguished member of the myositis research community who will discuss their research and its impact on the myositis community.
Dr. Kanneboyina Nagaraju (Raju) is an immunologist specializing in autoimmune myositis. His research, in collaboration with Drs. Eric Hoffman and John McCall led to the creation of a new prednisone-like anti-inflammatory drug that eliminates many of the challenging side effects of steroids.
Vamorolone is the first drug approved in both the US and Europe for the treatment of Duchenne muscular dystrophy. Dr. Raju expects myositis to be the next target of clinical trials for vamorolone.
This webinar will be moderated by David Mochel, MD, FACS, and Immediate Past Board Chair of TMA.
This was recorded May 21,2024.

[@Lost-In-Blank]

Thank you Dr Raju for all of your hard work over the years to develop this drug for us patients. And thank you to your collaborators and team members as well.

[@Lost-In-Blank]

I hope juvenile myositis will be an early candidate for a vamorolone trial.

[@Lost-In-Blank]

This is no sound ! There is no audio !

[@Lost-In-Blank]

It is fixed now. Thanks !